Literature DB >> 24274614

Emerging topical treatments for psoriasis.

Dario N Kivelevitch1, Katherine R Hebeler, Mahir Patel, Alan Menter.   

Abstract

INTRODUCTION: Psoriasis is an immune-mediated chronic inflammatory skin disease which classically presents as erythematous, scaly plaques affecting extensor surfaces of the limbs, scalp and trunk. Approximately 80% of patients have a mild-to-moderate form routinely treated with topical medications, whereas phototherapy, systemic and biological therapies are typically reserved for treatment of moderate-to-severe psoriasis. AREAS COVERED: The major advances in psoriasis therapy in the past 15 years have been in new immunomodulatory and biological molecules, with a significant unmet need to have new, efficient and safe topical treatment options for the large percentage of patients for whom systemic therapy is not indicated. The available topical therapies (corticosteroids and vitamin D3 analogs) have remained relatively unchanged over the past several decades. This article reviews emerging topical drugs and formulations currently under evaluation in clinical trials. EXPERT OPINION: The time is right for a revolution in our topical therapy armamentarium. It has lagged significantly behind the systemic biological evolution of new drug development. Our large psoriasis population with mild-to-moderate psoriasis certainly deserves potent but safe and innovative topical agents with a new mode of action as well as with long-lasting clinical efficacy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24274614     DOI: 10.1517/14728214.2013.861418

Source DB:  PubMed          Journal:  Expert Opin Emerg Drugs        ISSN: 1472-8214            Impact factor:   4.191


  6 in total

1.  Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis.

Authors:  Filomena Morisco; Maria Guarino; Serena La Bella; Luisa Di Costanzo; Nicola Caporaso; Fabio Ayala; Nicola Balato
Journal:  BMC Gastroenterol       Date:  2014-12-19       Impact factor: 3.067

2.  Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites.

Authors:  William R Swindell; Mrinal K Sarkar; Philip E Stuart; John J Voorhees; James T Elder; Andrew Johnston; Johann E Gudjonsson
Journal:  Clin Transl Med       Date:  2015-03-19

3.  Vitamin D supplementation of initially vitamin D-deficient mice diminishes lung inflammation with limited effects on pulmonary epithelial integrity.

Authors:  Shelley Gorman; Alysia G Buckley; Kak-Ming Ling; Luke J Berry; Vanessa S Fear; Stephen M Stick; Alexander N Larcombe; Anthony Kicic; Prue H Hart
Journal:  Physiol Rep       Date:  2017-08

4.  First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis.

Authors:  Sophie Glatt; Eric Helmer; Birgit Haier; Foteini Strimenopoulou; Graham Price; Pavan Vajjah; Olivier A Harari; John Lambert; Stevan Shaw
Journal:  Br J Clin Pharmacol       Date:  2017-01-10       Impact factor: 4.335

5.  Oxymatrine therapy inhibited epidermal cell proliferation and apoptosis in severe plaque psoriasis.

Authors:  H-J Shi; H Zhou; A-L Ma; L Wang; Q Gao; N Zhang; H-B Song; K-P Bo; W Ma
Journal:  Br J Dermatol       Date:  2019-05-20       Impact factor: 9.302

6.  A Randomized, Double-Blind, Controlled Clinical Study on the Curative Effect of Huaier on Mild-to-Moderate Psoriasis and an Experimental Study on the Proliferation of Hacat Cells.

Authors:  Dongqiang Su; Xuening Zhang; Likun Zhang; Jin Zhou; Feng Zhang
Journal:  Biomed Res Int       Date:  2018-08-29       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.